Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with hypercholesterolaemia |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The number and percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Measure | Description | Time Frame |
|---|---|---|
| The number and percentage of patients reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated | |
| The number and percentage of patients with high cardiovascular risk reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients treated by specialist
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vesna Loza, DOC. DR. SCI. MED | Klinika za bolesti srca i reumatizma Sarajevo , Bosnia and Herzegovina | Principal Investigator |
| Meta Jeras, MR PH | West Balkan MD | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Banja Luka | Bosnia and Herzegovina | ||||
| Research Site |
Not provided
Not provided
Not provided
Not provided
| During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| The number and percentage of patients with high cardiovascular risk reaching the total cholesterol goals, according to the Fourth Joint European Task Force guideline. | During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated |
| Bijeljina |
| Bosnia and Herzegovina |
| Research Site | Doboj | Bosnia and Herzegovina |
| Reserach Site | Gradiska | Bosnia and Herzegovina |
| Research Site | Kakanj | Bosnia and Herzegovina |
| Research Site | Maglaj | Bosnia and Herzegovina |
| Research Site | Prijedor | Bosnia and Herzegovina |
| Research Site | Sarajevo | Bosnia and Herzegovina |
| Research Site | Tešanj | Bosnia and Herzegovina |
| Research Site | Trebinje | Bosnia and Herzegovina |
| Research Site | Visoko | Bosnia and Herzegovina |
| Research Site | Zavidovići | Bosnia and Herzegovina |
| Research Site | Zenica | Bosnia and Herzegovina |
| Research Site | Zvornik | Bosnia and Herzegovina |
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided